Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System

• المؤلفون الرئيسيون: Vera Martins (مؤلف), Mafalda Jesus (مؤلف), Luísa Pereira (مؤلف), Cristina Monteiro (مؤلف), Ana Paula Duarte (مؤلف), Manuel Morgado (مؤلف)
• التنسيق: كتاب
• منشور في: MDPI AG, 2023-09-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are a recent targeted therapy approved for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer. Abemaciclib, palbociclib and ribociclib demonstrated great efficacy and saf...